MedPage Today (5/31, George) reports, “An index of gliosis was linked with persistent neurocognitive symptoms after mild or moderate SARS-CoV-2 infection, a small case-control study showed.” Data show that when “compared with healthy controls, PET measures of translocator protein total distribution volume, a marker of gliosis,” were “elevated in people with ongoing cognitive and depressive symptoms after COVID-19.” The findings were published online May 31 in JAMA Psychiatry.
Related Links:
— MedPage Today (requires login and subscription)